Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Sees Large Increase in Short Interest

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) was the target of a significant growth in short interest in August. As of August 14th, there was short interest totaling 17,905 shares, a growth of 102.8% from the July 30th total of 8,827 shares. Based on an average daily trading volume, of 102,216 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.6% of the company’s stock are sold short.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PBE. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Invesco Biotechnology & Genome ETF by 9,169.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 342,971 shares of the company’s stock valued at $28,175,000 after buying an additional 339,271 shares during the period. LPL Financial LLC grew its stake in Invesco Biotechnology & Genome ETF by 5.0% in the fourth quarter. LPL Financial LLC now owns 97,304 shares of the company’s stock valued at $7,994,000 after purchasing an additional 4,617 shares in the last quarter. United Capital Financial Advisors LLC acquired a new position in Invesco Biotechnology & Genome ETF in the 3rd quarter worth about $5,946,000. Royal Bank of Canada lifted its holdings in shares of Invesco Biotechnology & Genome ETF by 22.3% during the 1st quarter. Royal Bank of Canada now owns 75,402 shares of the company’s stock valued at $4,783,000 after buying an additional 13,767 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in shares of Invesco Biotechnology & Genome ETF by 2.5% in the 3rd quarter. Bank of America Corp DE now owns 59,918 shares of the company’s stock valued at $4,186,000 after buying an additional 1,453 shares in the last quarter.

Invesco Biotechnology & Genome ETF Stock Performance

Shares of Invesco Biotechnology & Genome ETF stock opened at $96.32 on Monday. Invesco Biotechnology & Genome ETF has a 1 year low of $67.69 and a 1 year high of $98.82. The company has a market cap of $303.41 million, a P/E ratio of 20.44 and a beta of 0.70. The stock has a 50-day moving average price of $92.06 and a 200 day moving average price of $84.78.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.